strategies aimed at limiting VEGF signaling through rAAV-mediated expression of soluble fms-like tyrosine kinase 1 (sFLT-1) have demonstrated some degree of efficacy in limiting CNV formation in pre-clinical animal models of wet AMD and have now progressed to Phase I/II clinical trials38,39,40...
Administration (FDA) approved (in 2008) in the USA, and three main clinical trials provided evidence of the usefulness of this gene expression signature.25–27 However, as for any other biomarkers, adoption in clinical practice is slow, and evidence that they have/will change practice are ...
This dose of 4.8 × 1013 vg/kg (1.3 × 1014 vg/kg, if assayed using a supercoiled DNA standard) is likely just below the highest dose currently being tested in the DMD (NCT: 03375164) and SMA (NCT: 02122952) clinical trials, which is 2 × 1014 vg/kg. Regardless, the use of dos...
We are different in some ways and the same in others. I’m hoping I’ll have better luck being more specific about how RA is affecting me personally. What would your list be like? Would it help explain your RA? Dear Person not living with RA: ...
Although the present findings do not allow predictions about clinical efficacy of LY379268, it is worth noting that the better assimilated analog LY404039 ameliorates both positive and negative symptoms in schizophrenia patients (Patil et al, 2007; Harrison, 2008). Some studies reported that LY...
If (secondary) surfactant deficiency were a major component in the clinical course of CDH, one would expect beneficial results from prenatal corticosteroid injections or surfactant replace- ment therapy, treatments that have dramatically reduced the mortality rate in surfactant-deficient RDS infants. ...
Methodologic rigor of clinical trials on surgical management of eyes with coexisting cataract and glaucoma. 2002;109:2215–24. View ArticleJampel HD, Friedman DS, Lubomski LH et al (2002) Effect of technique on intraocular pressure after combined cataract ... HD Jampel,DS Friedman,LH Lubomski...
Two clinical trials compared both dose regimens of ixekizumab with etanercept, showing superiority for ixekizumab (PASI 75 at week 12: 87.3–89.7% (Q2W) and 77.5–84.2% (Q4W) vs. 41.6–53.4%; p < 0.001). Results from sPGA 0/1 also showed ixekizumab superiority. Comparisons with ...
A simple immunohistochemical study for PD-L1 can identify patients prone to local recurrence, and such patients might benefit from more aggressive treatment in future clinical trials. Keywords: programmed death-ligand 1; nasopharyngeal carcinoma; Epstein-Barr virus; immunohistochemistry; radiotherapy; local...
This is more of a public health rather than a clinical approach to intervention implementation. 2.5.2. Individual-Level Clients will be randomized to receive one of the two mobile apps (CR or CR + eCBT), at the time of enrollment, with the assigned model delivered through the app. 2.6. ...